ARTICLE | Clinical News
Molecular Targeting regulatory update
November 13, 1995 8:00 AM UTC
The privately held Malvern, Penn., company received European Patent No. 438,502 covering its Amiscan product to detect acute myocardial infarction (AMI) and stroke. Molecular Targeting said Amiscan h...